Galantamine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Galantamine: From Alzheimer Disease to Psychogenic Movement Disorders
One-Sentence Summary
Galantamine is a cholinesterase inhibitor originally used to treat Alzheimer disease. The TxGNN model's top-ranked prediction is psychogenic movement disorders, but there are 0 clinical trials and 0 publications supporting this specific prediction. The strongest related evidence (20 publications, no registered trials) is for a different prediction, lingual-facial-buccal dyskinesia (tardive dyskinesia), and it is covered below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer disease (the Singapore licence records contain no approved indication text; this indication comes from the TxGNN knowledge graph) |
| Predicted New Indication | Psychogenic movement disorders |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, galantamine is an acetylcholinesterase inhibitor that also modulates nicotinic receptors. It has an established role in Alzheimer disease, where cholinergic signalling is reduced.
For psychogenic movement disorders, the link is weak. A link through cholinergic or nicotinic modulation of motor circuits is speculative, and a functional disorder has no established cholinesterase-inhibitor target. The high score appears to reflect proximity to other movement disorders in the knowledge graph rather than a specific mechanism.
Other predicted movement-related indications have somewhat better support:
- Lingual-facial-buccal dyskinesia (tardive dyskinesia): The rationale is cholinergic augmentation to restore the dopamine-acetylcholine balance in the striatum. Cochrane reviews and a meta-analysis of cholinergic drugs address the drug class rather than galantamine specifically, and have not established clear benefit. One randomized crossover trial of galantamine in tardive dyskinesia has been published.
- Extrapyramidal and movement disease: The literature is indirect. A 2025 systematic review reports movement disorders as an adverse-effect signal of cholinesterase inhibitors in Alzheimer dementia, which is a safety concern rather than a benefit.
- Other predictions (chronic tic disorder, primary orthostatic tremor, benign shuddering attacks, tremor-nystagmus-duodenal ulcer syndrome, benign paroxysmal tonic upgaze, acute intermittent porphyria, porphyria): prediction only, with no supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered for psychogenic movement disorders. No registered trials were identified for any of the other nine predicted indications either.
Literature Evidence
No literature is available for psychogenic movement disorders. The most relevant publications come from the neighbouring predictions, tardive dyskinesia and extrapyramidal/movement disease, and are shown here for context only.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17388711 | 2007 | RCT (crossover) | J Clin Psychiatry | 30-week double-blind, placebo-controlled crossover trial of galantamine in tardive dyskinesia |
| 29553158 | 2018 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Cholinergic medication for antipsychotic-induced tardive dyskinesia, class-level |
| 15610922 | 2004 | Meta-analysis | Prog Neuropsychopharmacol Biol Psychiatry | Meta-analysis of RCTs of cholinergic drugs, including galantamine, for neuroleptic-induced tardive dyskinesia |
| 12137608 | 2002 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Earlier Cochrane review of cholinergic medication for tardive dyskinesia |
| 23897874 | 2013 | Guideline | Neurology | American Academy of Neurology evidence-based guideline on treating tardive syndromes |
| 40224553 | 2025 | Systematic review | Brain Circulation | Movement disorders reported as adverse effects of cholinesterase inhibitors in Alzheimer dementia |
| 24127392 | 2014 | Pharmacovigilance study | Pharmacotherapy | Reporting of Pisa syndrome (a dystonia) with cholinesterase inhibitors in FDA adverse event data |
| 25734590 | 2015 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Cholinesterase inhibitors for rarer dementias associated with neurological conditions |
| 18938211 | 2008 | Preclinical (rat) | Neurosci Lett | Galantamine reduced striatal degeneration in a Huntington disease model |
| 25850380 | 2015 | Preclinical (mouse) | J Pharmacol Sci | Interaction of galantamine and donepezil with antipsychotic-induced extrapyramidal side effects |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13019P | REMINYL PROLONGED RELEASE CAPSULE 8 MG | Capsule, coated, extended release | Not recorded in the licence data |
| SIN13020P | REMINYL PROLONGED RELEASE CAPSULE 16 MG | Capsule, coated, extended release | Not recorded in the licence data |
| SIN13021P | REMINYL PROLONGED RELEASE CAPSULE 24 MG | Capsule, coated, extended release | Not recorded in the licence data |
All three licences are valid, single-ingredient, oral products from Janssen.
Safety Considerations
- Contraindications flagged in the knowledge graph (not taken from label text): familial long QT syndrome, atrioventricular block, liver failure and liver disease, kidney disease, epilepsy, asthma (including intrinsic and allergic forms), chronic obstructive pulmonary disease, peptic and duodenal ulcer disease, gallbladder disease, bladder neck obstruction, and pyoureter.
- Drug interactions: 100 interactions were found. Of the 20 shown, one is Major: bupropion. The rest are Moderate, including:
- Anticholinergic or antispasmodic agents: atropine, dicyclomine, hyoscyamine, glycopyrronium, clidinium, trospium.
- Acid-suppressing agents: famotidine, ranitidine, cimetidine.
- Others: clarithromycin, metronidazole, loperamide, and QT-relevant agents such as dolasetron and palonosetron.
- Movement-disorder signal: The 2025 systematic review and the Pisa syndrome pharmacovigilance study suggest cholinesterase inhibitors may themselves cause movement disorders. This matters for any use in movement-disorder populations.
- Porphyria predictions: The porphyria-related predictions need a porphyrinogenic drug-safety check before any consideration, because a metabolic trigger risk cannot be excluded from the available data.
Please refer to the package insert for full safety information. Warnings and contraindications from the label were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, psychogenic movement disorders, rests on the model score alone (L5), with no trials or literature, and no plausible mechanism. Galantamine is also marketed in Singapore, but only for its original indication, and its class has been linked to movement-disorder adverse effects.
To proceed, the following is needed:
- Mechanism of action data and the package insert warnings and contraindications from the Singapore Health Sciences Authority (HSA), which are currently missing.
- A direct literature and trial search for galantamine in psychogenic movement disorders.
- If a movement-disorder direction is pursued, tardive dyskinesia is the more evidence-supported candidate (L4, "Research Question"). It would need a review of the existing galantamine crossover trial (PMID 17388711) and of the class-level Cochrane findings.
- A safety review of the QT, cardiac conduction, and anticholinergic interactions, plus the movement-disorder adverse-effect signal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.